Literature DB >> 11389057

Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma.

S Monestiroli1, P Mancuso, A Burlini, G Pruneri, C Dell'Agnola, A Gobbi, G Martinelli, F Bertolini.   

Abstract

Circulating endothelial cells (CECs) were evaluated by flow cytometry in immunodeficient mice bearing human lymphoma. A trend toward higher CEC values was observed on days 7 and 14 after transplant, and differences versus controls were highly significant on day 21 (P = 0.0061). A strong correlation was found between CEC and tumor volume (r, 0.942; P = 0.004) and between CEC and tumor-generated VEGF (r, 0.669; P = 0.02). In mice given cyclophosphamide, most of the circulating apoptotic cells were hematopoietic and not endothelial. Conversely, in mice given endostatin, all of the increase in apoptotic cells was in the endothelial cell compartment. CEC evaluation is promising as a noninvasive, surrogate angiogenesis marker.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389057

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy.

Authors:  Guido Bocci; Giulio Francia; Shan Man; Jack Lawler; Robert S Kerbel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-15       Impact factor: 11.205

2.  Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.

Authors:  Sang Joon Shin; Jee Won Hwang; Joong Bae Ahn; Sun Young Rha; Jae Kyung Roh; Hyun Cheol Chung
Journal:  Invest New Drugs       Date:  2012-04-27       Impact factor: 3.850

3.  A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.

Authors:  Alison T Stopeck; Joseph M Unger; Lisa M Rimsza; William T Bellamy; Maria Iannone; Daniel O Persky; Michael Leblanc; Richard I Fisher; Thomas P Miller
Journal:  Leuk Lymphoma       Date:  2009-05

4.  Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers.

Authors:  Jacek Treliński; Agnieszka Wierzbowska; Anna Krawczyńska; Agata Sakowicz; Tadeusz Pietrucha; Piotr Smolewski; Tadeusz Robak; Krzysztof Chojnowski
Journal:  Int J Hematol       Date:  2010-05-15       Impact factor: 2.490

5.  Angiopoietins in haematopoietic stem cell mobilisation in patients with haematological malignancies.

Authors:  Anna Szmigielska-Kaplon; Anna Krawczynska; Magdalena Czemerska; Agnieszka Pluta; Barbara Cebula-Obrzut; Katarzyna Szmigielska; Konrad Stępka; Piotr Smolewski; Tadeusz Robak; Agnieszka Wierzbowska
Journal:  Blood Transfus       Date:  2014-09-12       Impact factor: 3.443

6.  A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.

Authors:  R J Schilder; M W Sill; H A Lankes; M A Gold; R S Mannel; S C Modesitt; P Hanjani; A J Bonebrake; A K Sood; A K Godwin; W Hu; R K Alpaugh
Journal:  Gynecol Oncol       Date:  2013-01-13       Impact factor: 5.482

7.  Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin.

Authors:  Yuki Hamano; Michael Zeisberg; Hikaru Sugimoto; Julie C Lively; Yohei Maeshima; Changqing Yang; Richard O Hynes; Zena Werb; Akulapalli Sudhakar; Raghu Kalluri
Journal:  Cancer Cell       Date:  2003-06       Impact factor: 31.743

8.  Atherosclerosis and vascular aging as modifiers of tumor progression, angiogenesis, and responsiveness to therapy.

Authors:  Halka Klement; Brad St Croix; Chloe Milsom; Linda May; Qing Guo; Joanne L Yu; Petr Klement; Janusz Rak
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

9.  Metronomic chemotherapy: changing the paradigm that more is better.

Authors:  O G Scharovsky; L E Mainetti; V R Rozados
Journal:  Curr Oncol       Date:  2009-03       Impact factor: 3.677

Review 10.  The role of angiogenesis in human non-Hodgkin lymphomas.

Authors:  Domenico Ribatti; Beatrice Nico; Girolamo Ranieri; Giorgina Specchia; Angelo Vacca
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.